Literature DB >> 30312223

Predictors of Metastases in Rectal Neuroendocrine Tumors: Results of a National Cohort Study.

Seth J Concors1,2, Andrew J Sinnamon1,2, Ian W Folkert1,2, Najjia N Mahmoud1,2, Douglas L Fraker1,2, E Carter Paulson1,2, Robert E Roses1,2.   

Abstract

BACKGROUND: Rectal neuroendocrine tumors are often found incidentally. Local excision alone has been advocated for lesions ≤2 cm; however, the evidence base for this approach is limited.
OBJECTIVE: Associations among tumor size, degree of differentiation, and presence of distant metastatic disease were examined.
DESIGN: This was a retrospective cohort study. SETTINGS: This study was conducted using a nationwide cohort. PATIENTS: A total of 4893 patients with rectal neuroendocrine tumors were identified in the National Cancer Database (2006-2015). MAIN OUTCOME MEASURES: Logistic regression analyses were used to evaluate associations among tumor size, degree of differentiation, and presence of regional and distant metastatic disease. Cut point analysis was performed to identify an optimal size threshold predictive of distant metastatic disease.
RESULTS: Of patients included for analysis, 3880 (79.3%) had well-differentiated tumors, 540 (11.0%) had moderately differentiated tumors, and 473 (9.7%) had poorly differentiated tumors. On logistic regression, increasing size was associated with a higher likelihood of pathologically confirmed lymph node involvement (among patients undergoing proctectomy), and both size and degree of differentiation were independently associated with a higher likelihood of distant metastatic disease. The association between tumor size and distant metastatic disease was stronger for well-differentiated and moderately differentiated tumors (OR = 1.4; p < 0.001 for both) than for poorly differentiated tumors (OR = 1.1; p = 0.010). For well-differentiated tumors, the optimal cut point for the presence of distant metastatic disease was 1.15 cm (area under the curve = 0.88; 88% sensitive and 88% specific). Tumors ≥1.15 cm in diameter were associated with a substantially increased incidence of distant metastatic disease (72/449 (13.8%)). For moderately differentiated tumors, the optimal cut point was also 1.15 cm (area under the curve = 0.87, 100% sensitive and 75% specific). LIMITATIONS: This study was limited by its retrospective design.
CONCLUSIONS: Tumor size and degree of differentiation are predictive of regional and distant metastatic disease in rectal neuroendocrine tumors. Patients with tumors >1.15 cm are at substantial risk of distant metastasis and should be staged and managed accordingly. See Video Abstract at http://links.lww.com/DCR/A778.

Entities:  

Mesh:

Year:  2018        PMID: 30312223     DOI: 10.1097/DCR.0000000000001243

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  10 in total

1.  A novel preoperative risk score to predict lymph node positivity for rectal neuroendocrine tumors: An NCDB analysis to guide operative technique.

Authors:  Adriana C Gamboa; Yuan Liu; Rachel M Lee; Mohammad Y Zaidi; Charles A Staley; Maria C Russell; Kenneth Cardona; Patrick S Sullivan; Shishir K Maithel
Journal:  J Surg Oncol       Date:  2019-08-26       Impact factor: 3.454

2.  Effects of tumor distance from anal verge on survival outcomes for rectal NENs and lymphatic metastasis risk score for colorectal NENs.

Authors:  Xiaoling Duan; Man Zhao; Shenglei Zhang; Zhibin Xu; Lili Mi; Jianfei Shi; Xiaoying Ma; Yueping Liu; Ning Li; Xiaolei Yin; Xin Han; Guangjie Han; Jinfeng Wang; Jinsheng Xu; Fei Yin
Journal:  Int J Colorectal Dis       Date:  2020-04-20       Impact factor: 2.571

Review 3.  Rectal neuroendocrine neoplasms: what the radiologists should know.

Authors:  Mayur Virarkar; Dheeraj R Gopireddy; Ajaykumar C Morani; Ahmad Alkhasawneh; Sergio Piotr Klimkowski; Sindhu Kumar; Chandana Lall; Priya Bhosale
Journal:  Abdom Radiol (NY)       Date:  2022-03-14

4.  Epidemiological, clinical and endoscopic characteristics of colorectal neuroendocrine neoplasms: a population-based study in the Netherlands.

Authors:  Ankie Reumkens; Prapto Sastrowijoto; Heike I Grabsch; Danny Goudkade; Chantal le Clercq; Minke Bakker; Eric Keulen; Rogier de Ridder; Wouter W de Herder; Bjorn Winkens; Silvia Sanduleanu; Judith de Vos-Geelen; Ad Masclee
Journal:  Endosc Int Open       Date:  2022-07-15

5.  Grade G2 Rectal Neuroendocrine Tumor Is Much More Invasive Compared With G1 Tumor.

Authors:  Yi-Wei Li; Yi-Ping He; Fang-Qi Liu; Jun-Jie Peng; San-Jun Cai; Ye Xu; Ming-He Wang
Journal:  Front Oncol       Date:  2021-03-11       Impact factor: 6.244

6.  Outcomes for a Large Cohort of Patients with Rectal Neuroendocrine Tumors: an Analysis of the National Cancer Database.

Authors:  Beiqun Zhao; Hannah M Hollandsworth; Nicole E Lopez; Lisa A Parry; Benjamin Abbadessa; Bard C Cosman; Sonia L Ramamoorthy; Samuel Eisenstein
Journal:  J Gastrointest Surg       Date:  2020-02-03       Impact factor: 3.452

7.  Risk Factors for Development of Rectal Neuroendocrine Tumors Longer Than 9 mm: Retrospective Cohort.

Authors:  Juliana Silveira Lima de Castro; Evandra Cristina Vieira da Rocha; Vanessa Assis do Vale; Paula Mendonça; Oswaldo Wiliam Marques; Eloy Taglieri; Francisco Susumu Correa Koyama; Celso Augusto Milani Cardoso Filho; Wilson Toshihiko Nakagawa
Journal:  Turk J Gastroenterol       Date:  2021-08       Impact factor: 1.852

8.  Rectal NETs and rectosigmoid junction NETs may need to be treated differently.

Authors:  Wen Cai; Weiting Ge; Hanguang Hu; Jianshan Mao
Journal:  Cancer Med       Date:  2019-12-16       Impact factor: 4.452

9.  Assessment of the Risk of Nodal Involvement in Rectal Neuroendocrine Neoplasms: The NOVARA Score, a Multicentre Retrospective Study.

Authors:  Angela Dalia Ricci; Sara Pusceddu; Francesco Panzuto; Fabio Gelsomino; Sara Massironi; Claudio Giovanni De Angelis; Roberta Modica; Gianluca Ricco; Martina Torchio; Maria Rinzivillo; Natalie Prinzi; Felice Rizzi; Giuseppe Lamberti; Davide Campana
Journal:  J Clin Med       Date:  2022-01-28       Impact factor: 4.241

Review 10.  Rectal neuroendocrine tumors: Current advances in management, treatment, and surveillance.

Authors:  Camilla Gallo; Roberta Elisa Rossi; Federica Cavalcoli; Federico Barbaro; Ivo Boškoski; Pietro Invernizzi; Sara Massironi
Journal:  World J Gastroenterol       Date:  2022-03-21       Impact factor: 5.742

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.